Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (January 2020)
21 slides from Cynata Therapeutics's investor presentation, Jan 31, 2020
Slide 1: ASX Announcement: Cynata Investor Presentation
For personal use only ASX ANNOUNCEMENT 31 January 2020 Cynata Investor Presentation Melbourne, Australia; 31 January 2020: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has today released a new investor presentation. Cynata will use
Slide 2: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company Proactive CEO Event - Investor Presentation: Cynata Therapeutics Limited February 2020
Slide 3: Important Information
Important Information For personal use only This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain
Slide 4: Phase II-ready biotech with a scalable proprietary stem cell platform
Cynata Therapeutics is a Phase II-ready biotech with a highly scalable, proprietary platform for developing stem cell therapeutics For personal use only Our focus Utilise our proprietary CymerusTM platform technology to develop commercially scalable cellular therapeutic products to treat serious chr
Slide 5: Investment Highlights
Investment Highlights For personal use only Outstandingly well positioned in regenerative medicine Scalable, globally applicable technology Successful clinical trial results: world leader Attractive and validated licensing business model Clear pipeline of high potential target areas www.cynata.com 4
Slide 6: What are Mesenchymal Stem Cells (MSCs)?
What are Mesenchymal Stem Cells (MSC’s)? For personal use only Stem Cells: A A• have the ability to divide and create an identical copy of themselves (ie. ‘self-renew’) B• can divide and differentiate to form mature cells (e.g. skin cells, nerve cells, muscle cells etc) B Mesenchymal Stem Cells: MSC
Slide 7: Cymerus platform enables production of MSCs from a single adult donor
Our patented Cymerus platform enables the production of MSC’s from a single adult donor For personal use only To watch an animation of our Cymerus technology please click here: https://www.cynata.com/#home www.cynata.com 6
Slide 8: Cynata's MSCs are high quality and commercially scalable
Cynata‘s MSCs are high quality and commercially scalable For personal use only Key advantages of the Cymerus process Consistent product quality – single donor overcomes regulatory concerns CONSISTENCY Bypasses complex and invasive surgeries with a scalable and cost-effective process, & SCALABILI
Slide 9: Executing on a clear scientific and commercial vision
Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value For personal use only Multiple options to create shareholder value case study Build value in platform independently Exclusive global licence in GvHD Multiple cash flow
Slide 10: Value inflection point following clear data
Value inflection point following clear data For personal use only Successful Phase 1 clinical trial data demonstrating efficacy of Cynata‘s technology platform Successful clinical trial results with all endpoints achieved1 Complete Response2 Overall Response3 Overall survival4 53% rate 87% rate ≥8
Slide 11: Cymerus platform has potential applications across a wide range of diseases
Cynata's Cymerus platform has potential applications across a wide range of diseases For personal use only Crohn’s Graft vs Host Disease Disease Others (GvHD) Fistula Coronary Artery Disease (CAD) Potential future target areas Licensed1 Cytokine Release Syndrome CYP-001 Osteoarthritis (funded by N
Slide 12: Cynata is well placed in an increasingly validated MSC market
Cynata is well placed in a increasingly validated MSC market For personal use only Clinical use of MSCs Cynata is well placed in the continues to grow MSC-based therapy market ~6 approved MSC therapies now Many ongoing Phase 3 trials involve very on the market1 common conditions, representing multi-
Slide 13: Significant upside potential based on Mesoblast market valuation
Significant upside potential based on Mesoblast market valuation For personal use only Market capitalisation 1,610 (A$m)1 113 ASX listed Focus • Regenerative and cellular medicine • Regenerative and cellular medicine Products in • TEMCELL® (via licensee JCR Pharmaceuticals Co., Ltd) market • Alo
Slide 14: Cynata is targeting significant market opportunities
Cynata is targeting significant market opportunities For personal use only TARGET AREA TRIAL PHASE MARKET OPPORTUNITY Graft vs. Host Entering Clinical US $0.3bn1 Disease (GvHD) Phase II Critical limb Entering Clinical Phase II US $1.4bn2 ischemia (CLI) Entering Clinical Osteoarthritis (OA) Phase II
Slide 15: Outlook
Outlook Cynata has a large pipeline of indications with upcoming catalysts Today For personal use only H1 CY2019 H2 CY2019 H1 CY2020 Upcoming catalysts / status Phase II trial expected to commence Graft vs in CY2020; FUJIFILM to bear Phase II trial planning Host Disease license responsibility for fu
Slide 16: Thank you for your attention
For personal use only Thank you for your attention Cynata Therapeutics Limited Contact details: Level 3 62 Lygon Street ross.macdonald@cynata.com Carlton Victoria 3053 www.cynata.com Australia
Slide 17: Appendix
For personal use only Appendix
Slide 18: Investment Summary
Investment Summary For personal use only • Cymerus platform technology enables commercial-scale production of mesenchymal stem cells Scalable, globally 1 • Fully patented process overcomes multiple issues with today’s on-market solutions applicable technology • Value of platform to a range of diseas
Slide 19: Globally experienced board and management team
Globally experienced board and management team For personal use only Dr Paul Wotton Dr Ross Macdonald Dr Stewart Washer Dr Geoff Brooke Mr Peter Webse Dr Kilian Kelly Chairman Managing Director / CEO Non-Exec Director Non-Exec Director Non-Exec Director Chief Operating Officer Company Secretary CE
Slide 20: GvHD clinical trial results
GvHD clinical trial results Clinical trial design and key implications of clinical trial results For personal use only Graft versus host disease (GVHD) is a condition where following a transplant the donor’s immune cells in the transplant What is (graft) make antibodies against the patient's tissues
Slide 21: GvHD clinical trial results
GvHD clinical trial results Highly successful outcome, with majority of patients reporting a Complete Response from a devastating disease For personal use only Phase I clinical trial data – all endpoints achieved1 Complete Response2 Overall Response3 Overall survival4 53% rate 87% rate ≥87% rate Pat
Cynata Therapeutics — Investor Presentation (January 2020) on 6ix